OLIGODENDROGLIOMA

This study tests a drug called safusidenib in people with a type of brain tumor (glioma) that has a specific gene mutation (IDH1). The trial has three parts: one for recurrent tumors, one for high-risk tumors after standard treatment, and one for a specific tumor type after surge…

This study tests whether adding the drug olutasidenib to standard chemotherapy (temozolomide) can help children and young adults with a specific type of brain cancer (IDH1-mutant high-grade glioma) live longer. About 60 participants will receive the combination as maintenance the…

This study compares proton therapy to standard photon radiation for people with slow-growing brain tumors (IDH-mutated gliomas). The goal is to see if proton therapy, which targets tumors more precisely, can reduce side effects and maintain quality of life without shortening surv…

This phase 2 trial tests a combination of two drugs—all-trans retinoic acid (ATRA) and retifanlimab—in 55 people with recurrent IDH-mutant glioma, a type of brain tumor. The goal is to see if the combo can shrink tumors or slow their growth. Participants take ATRA pills for 14 da…

This phase 3 trial tests a new chemotherapy combination (CETEG) for adults with a slow-growing brain tumor called oligodendroglioma. The goal is to see if starting with chemo alone can delay or avoid radiation therapy, which can cause long-term cognitive and quality-of-life probl…

This study is for people with a specific type of slow-growing brain tumor (oligodendroglioma) that needs treatment beyond surgery. The goal is to see if waiting to start radiation until the tumor grows back can help protect memory and thinking skills, without shortening how long …

This study tests a more intense treatment for a fast-growing type of brain cancer called IDH wildtype glioma. It combines higher doses of radiation with the chemotherapy drug temozolomide to try to stop the tumor from growing longer. The trial will enroll 40 adults with this spec…

This early-stage study tests an oral drug called ONC206 in adults with brain tumors that have come back. The main goal is to find the safest dose and check for side effects. About 102 participants will take the drug once or several times a week.

This early-phase trial tests a personalized vaccine called Tamavaq NeoVaccine in 29 adults with newly diagnosed glioma, a type of brain cancer. The vaccine is custom-made for each patient using AI and quantum mechanics to target unique cancer markers. The main goal is to check if…

This study tests whether giving two drugs (cetuximab and bevacizumab) directly into the brain's blood vessels each month is safe and can shrink tumors or slow their growth. It includes children and young adults under 22 with certain types of brain tumors that have come back or no…

This phase 2 trial tests tarlatamab, a drug that helps immune cells attack tumor cells, in 44 adults with recurrent IDH-mutant gliomas (a type of brain tumor). The study aims to see if tarlatamab can increase immune cell activity in the tumor and potentially control the disease. …

This study tests a home-based program called HOBSCOTCH-CA for brain cancer survivors who struggle with memory and thinking. The program involves weekly virtual sessions with a coach, teaching problem-solving and relaxation techniques. Researchers will compare two groups: one that…

This study is testing a new virtual therapy program called FearLess, designed to help people with primary malignant brain tumors and their caregivers cope with the intense fear that their cancer might come back. The program involves 8 weekly one-on-one video sessions with a thera…

This study looks at why some people with brain tumors (gliomas) develop low blood cell counts from the drug temozolomide, while others don't. Researchers will analyze genes, gut bacteria, and other factors in 55 patients to find clues. The goal is to help doctors predict and prev…